Epidermal growth factor receptor tyrosine kinase domain (EGFR-TK or EGFR tyrosine kinase)

The **epidermal growth factor receptor tyrosine kinase domain** is the intracellular catalytic region of the epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases[1][2][3][4][5][6][7]. Upon activation by extracellular ligand-induced dimerization, the kinase domain initiates signal transduction by phosphorylating specific tyrosine residues on the receptor's intracellular tail, recruiting downstream signaling molecules that drive processes such as cell proliferation, differentiation, and survival[1][3][4][7]. Structurally, the kinase domain consists of a bi-lobed fold (N-lobe and C-lobe) with a deep ATP-binding cleft, a glycine-rich phosphate-binding loop, and regulatory elements such as the αC-helix and activation loop (A-loop) containing a conserved DFG motif[2][4]. Aberrant activation, amplification, or mutation of the EGFR kinase domain is implicated in many cancers, especially lung adenocarcinoma, and targeting this domain with small-molecule kinase inhibitors is a cornerstone of precision oncology[5][6][8]. Resistance to inhibitors can develop due to secondary mutations, requiring next-generation drugs targeting specific altered conformations or covalently binding to unique residues[8]. The domain's function as an oncogenic driver and validated drug target has led to the development of numerous tyrosine kinase inhibitors, with defined molecular and clinical biomarkers guiding therapy choices[8][3][6][7].

Other names

EGFR kinase domainEGFR-TKErbB1 tyrosine kinase domainERBB tyrosine kinaseEpidermal growth factor receptor kinase domain

Inhibition of ATP binding to the kinase domain (competitive inhibition); Irreversible covalent binding to active site cysteine (for some drugs); Allosteric inhibition (in development/experimental)